Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; indigo carmine; hypromellose; iron oxide yellow; triacetin - arcoxia is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etoricoxib, quantity: 60 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; carnauba wax; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; indigo carmine; hypromellose; iron oxide yellow; triacetin - arcoxia is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etoricoxib, quantity: 30 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; carnauba wax; croscarmellose sodium; titanium dioxide; indigo carmine aluminium lake; lactose monohydrate; hypromellose; iron oxide yellow; triacetin - arcoxia is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - etoricoxib - arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 120mg; etoricoxib 120mg - film coated tablet - 120 mg - active: etoricoxib 120mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water active: etoricoxib 120mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 30mg - film coated tablet - 30 mg - active: etoricoxib 30mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11526 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 60mg; etoricoxib 60mg - film coated tablet - 60 mg - active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 90mg; etoricoxib 90mg - film coated tablet - 90 mg - active: etoricoxib 90mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water active: etoricoxib 90mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.